This company listing is no longer active
G5Z Stock Overview
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Neovasc Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | CA$27.00 |
| 52 Week High | CA$28.00 |
| 52 Week Low | CA$4.50 |
| Beta | 1.98 |
| 1 Month Change | -0.74% |
| 3 Month Change | 45.16% |
| 1 Year Change | 208.57% |
| 3 Year Change | -50.00% |
| 5 Year Change | -96.82% |
| Change since IPO | -99.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| G5Z | DE Medical Equipment | DE Market | |
|---|---|---|---|
| 7D | 0% | 0.7% | 2.5% |
| 1Y | 208.6% | -4.6% | 6.0% |
Return vs Industry: G5Z exceeded the German Medical Equipment industry which returned -3.4% over the past year.
Return vs Market: G5Z exceeded the German Market which returned -7% over the past year.
Price Volatility
| G5Z volatility | |
|---|---|
| G5Z Average Weekly Movement | 9.0% |
| Medical Equipment Industry Average Movement | 4.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.4% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: G5Z's share price has been volatile over the past 3 months.
Volatility Over Time: G5Z's weekly volatility (9%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2000 | 60 | Fred Colen | neovasc.com |
Neovasc Inc., a specialty medical device company, develops, manufactures, and markets products for cardiovascular marketplace in Europe and internationally. Its products include Tiara for the transcatheter treatment of mitral valve disease; and the Neovasc Reducer for the treatment of refractory angina. The company was formerly known as Medical Ventures Corp. and changed its name to Neovasc Inc. in July 2008.
Neovasc Inc. Fundamentals Summary
| G5Z fundamental statistics | |
|---|---|
| Market cap | €74.97m |
| Earnings (TTM) | -€37.50m |
| Revenue (TTM) | €3.46m |
21.6x
P/S Ratio-2.0x
P/E RatioIs G5Z overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| G5Z income statement (TTM) | |
|---|---|
| Revenue | US$3.81m |
| Cost of Revenue | US$5.07m |
| Gross Profit | -US$1.27m |
| Other Expenses | US$39.93m |
| Earnings | -US$41.20m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -14.93 |
| Gross Margin | -33.37% |
| Net Profit Margin | -1,082.90% |
| Debt/Equity Ratio | 79.8% |
How did G5Z perform over the long term?
See historical performance and comparison